| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA4383327 | B | Inhibition of human sPLA2 | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 2. | ALA4383350 | B | Inhibition of human sPLA2 at 10 uM relative to control | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 3. | ALA4413451 | B | Inhibition of human recombinant sPLA2 assessed as reduction in 16:0 LPC formation after 30 mins by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 4. | ALA4413461 | B | Inhibition of human recombinant sPLA2 assessed as reduction in free FA formation after 30 mins by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 5. | ALA4413463 | B | Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in 16:0 LPA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 6. | ALA4413464 | B | Inhibition of human recombinant sPLA2 using PAPC as substrate assessed as reduction in 16:0 LPC formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 7. | ALA4413465 | B | Inhibition of human recombinant sPLA2 using PAPE as substrate assessed as reduction in 16:0 LPE formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 8. | ALA4413466 | B | Inhibition of human recombinant sPLA2 using PAPG as substrate assessed as reduction in 16:0 LPG formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 9. | ALA4413467 | B | Inhibition of human recombinant sPLA2 using PAPS as substrate assessed as reduction in 16:0 LPS formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 10. | ALA4413468 | B | Inhibition of human recombinant sPLA2 using PAPA as substrate assessed as reduction in free FA formation after 30 mins in presence of equal molar mixture of PAPA/PAPC/PAPE/PAPG/PAPS/PLPC by HPLC-MS analysis | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 11. | ALA4413469 | B | Ratio of XI50 for inhibition of human recombinant sPLA2 using PAPG to XI50 for inhibition of human recombinant sPLA2 using PAPC | Homo sapiens | 1 | protein format | Scientific Literature | ||
| 12. | ALA4431154 | B | Inhibition of sPLA2 in human plasma using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay | Homo sapiens | 11 | cell-free format | Scientific Literature | ||
| 13. | ALA4431158 | B | Inhibition of sPLA2 in human plasma at 25 uM using 1-Hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphomethanol as substrate preincubated for 10 mins followed by substrate addition measured after 90 mins by fluorescence assay | Homo sapiens | 1 | cell-free format | Scientific Literature | ||
| 14. | ALA4431199 | B | Inhibition of sPLA2 in human HepG2 cells | Homo sapiens | 1 | cell-based format | Scientific Literature | ||
| 15. | ALA4431200 | B | Inhibition of sPLA2 in atherosclerotic plaque from coronary artery disease patient | Homo sapiens | 1 | protein format | Scientific Literature |
The page will load shortly, Thanks for your patience!